Stifel Maintains Hold on Denali Therapeutics, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Mattels maintains a Hold rating on Denali Therapeutics (DNLI) and lowers the price target from $26 to $22.
May 08, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst Paul Mattels maintains a Hold rating on Denali Therapeutics and lowers the price target from $26 to $22.
The reduction in price target by Stifel suggests a bearish outlook on DNLI's short-term price potential, likely leading to negative investor sentiment and a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100